ATOS
NASDAQ · Biotechnology
Atossa Therapeutics Inc
$5.11
-0.15 (-2.85%)
Financial Highlights (FY 2025)
Revenue
21.66M
Net Income
-1,423,753
Gross Margin
30.3%
Profit Margin
-6.6%
Rev Growth
+8.7%
D/E Ratio
0.16
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 30.3% | 30.3% | 30.3% |
| Operating Margin | -6.1% | -7.5% | -6.4% |
| Profit Margin | -6.6% | -8.7% | -7.6% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.66M | 19.11M | 19.03M |
| Gross Profit | 6.56M | 5.79M | 5.77M |
| Operating Income | -1,316,353 | -1,430,945 | -1,209,185 |
| Net Income | -1,423,753 | -1,667,488 | -1,447,772 |
| Gross Margin | 30.3% | 30.3% | 30.3% |
| Operating Margin | -6.1% | -7.5% | -6.4% |
| Profit Margin | -6.6% | -8.7% | -7.6% |
| Rev Growth | +8.7% | -4.8% | +0.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 4.98M | 4.68M | 4.53M |
| Total Equity | 31.98M | 36.10M | 34.30M |
| D/E Ratio | 0.16 | 0.13 | 0.13 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -1,912,051 | -1,729,452 | -1,852,839 |
| Free Cash Flow | -992,506 | -967,985 | -917,697 |